Differential regulation of interleukin 17 and interferon   production in inflammatory bowel disease

Background and Aims: Interleukin 17 (IL17) is now known to be involved in a number of chronic inflammatory disorders. However, the mechanisms regulating its production in inflammatory bowel disease (IBD) are still unclear. Methods: Endoscopic biopsies or surgical specimens were taken from inflamed and uninflamed colonic mucosa of 72 patients with IBD (38 with Crohn's disease and 34 with ulcerative colitis), and normal colon of 38 control subjects. IL17 and interferon [GAMMA] (IFN[GAMMA]) were detected by ELISA in the supernatants of biopsies cultured ex vivo, and anti-CD3/CD28-stimulated lamina propria mononuclear cells (LPMCs) incubated with IL12, IL23, IL1β plus IL6, transforming growth factor β1 (TGFβ1), or anti-IL21 neutralising antibody. Intracellular flow cytometry was performed to analyse mucosal Th17 and Th1/Th17 cells. Results: IL17 production by organ culture biopsies was higher in IBD inflamed mucosa than IBD uninflamed mucosa and controls, and was equivalent in amount to IFN[GAMMA]. Anti-CD3/CD28-stimulated IBD LPMCs produced higher IL17 amounts compared to controls. The percentages of Th17 and Th1/Th17 cells were increased in patients with IBD. IL23 and IL1β plus IL6 had no effect on IBD LPMC production of IL17; however, IL12 markedly increased IFN[GAMMA] production and decreased IL17 production. TGFβ1 dose-dependently decreased IFN[GAMMA], but had no significant inhibitory effect on IL17 production. Blocking IL21 significantly downregulated IL17 production. Conclusions: Our findings support a role for IL12, TGFβ and IL21 in modulating IL17/IFN[GAMMA] production in IBD. The abundant IL17 in inflamed IBD mucosa may help explain the relative lack of efficacy of anti-IFN[GAMMA] antibodies in clinical trials of Crohn's disease.